9 results on '"Vignetti, M."'
Search Results
2. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients.
- Author
-
Iacobucci, I., Lonetti, A., Messa, F., Ferrari, A., Cilloni, D., Soverini, S., Paoloni, F., Arruga, F., Ottaviani, E., Chiaretti, S., Messina, M., Vignetti, M., Papayannidis, C., Vitale, A., Pane, F., Piccaluga, P. P., Paolini, S., Berton, G., Baruzzi, A., and Saglio, G.
- Subjects
LYMPHOCYTIC leukemia ,LYMPHOBLASTIC leukemia ,PROTEIN-tyrosine kinases ,CHROMOSOME polymorphism ,DIAGNOSIS ,PROGNOSIS - Abstract
The main reason for the unfavorable clinical outcome of BCR–ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induced cytidine deaminase (AID) and its role in clinical outcome in 61 adult BCR–ABL1-positive ALL patients. AID expression was detected in 36 patients (59%); it correlated with the BCR–ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors. Different AID splice variants were identified: full-length isoform; AIDΔE4a, with a 30-bp deletion of exon 4; AIDΔE4, with the exon 4 deletion; AIDins3, with the retention of intron 3; AIDΔE3-E4 isoform without deaminase activity. AID-FL predominantly showed cytoplasmic localization, as did the AID-ΔE4a and AID-ΔE3E4 variants, whereas the C-terminal-truncated AID-ΔE4 showed a slightly increased nuclear localization pattern. AID expression correlated with a higher number of copy number alterations identified in genome-wide analysis using a single-nucleotide polymorphism array. However, the expression of AID at diagnosis was not associated with a worse prognosis. In conclusion, BCR–ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
3. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
- Author
-
Amadori, S., Suciu, S., Stasi, R., Willemze, R., Mandelli, F., Selleslag, D., Denzlinger, C., Muus, P., Stauder, R., Berneman, Z., Pruijt, J., Nobile, F., Cassibba, V., Marie, J.-P., Beeldens, F., Baila, L., Vignetti, M., and de Witte, T.
- Subjects
MYELOID leukemia ,BONE marrow diseases ,FRAIL elderly ,DISEASES in older people ,ANTIBODY-toxin conjugates ,CD antigens - Abstract
The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were not considered eligible for conventional chemotherapy because of advanced age or poor performance status. The drug was administered at the dose of 9 mg/m2 as a single 2-h i.v. infusion on days 1 and 15. Patients who achieved a complete remission (CR/CRp) were to receive a consolidation with two additional injections of the immunotoxin at the same dose. The overall CR/CRp rate was 17% (95% CI, 8-32%). The CR/CRp rate in patients 61-75 years old was 33% (6/18), and 5% (1/22) in patients older than 75 years. Induction death occurred in seven patients (17%), all aged above 75 years. Overall survival was significantly longer in patients aged 61-75 years than in older individuals (P=0.05), and in CD33+ cases than in CD33- cases (P=0.05). We conclude that the dose/schedule of gemtuzumab ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients, additional studies with reduced doses of the immunotoxin are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
4. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia.
- Author
-
Rizzo, MG, Giombini, E, Diverio, D, Vignetti, M, Sacchi, A, Testa, U, Lo-Coco, F, Blandino, G, and Rizzo, M G
- Subjects
ACUTE myeloid leukemia ,GENE expression ,CANCER ,APOPTOSIS ,CELL differentiation - Abstract
p73, the homologue of p53, is a nuclear protein whose ectopic expression, in p53+/+ and p53-/- cells, recapitulates the most well-characterized p53 effects, such as growth arrest, apoptosis and differentiation. Unlike p53, which is mutated in half of human cancers, p73 is rarely mutated. However, altered expression of the p73 gene has been reported in neuroblastoma, lung cancer, prostate cancer and renal cell carcinoma. To investigate the potential involvement of p73 in acute myeloid leukemias (AMLs), we analyzed 71 samples from AML patients for the expression pattern of N-terminal transactivation-p73alpha (TA-p73alpha), its spliced isoforms and N-terminal-deleted-p73 transcripts (DeltaN-p73). We detected p73 gene expression in AML irrespective of FAB (French-American-British) subtypes. Notably, the analysis of DeltaN-p73 expression, which has been reported to inactivate both p53 and p73 antitumor effects, revealed a rather peculiar pattern. In fact, DeltaN-p73 transcript and protein were detectable in 27/28 (96.4%) cases of M0, M1, M2, M4, M5 and M6 AML and in 13/41 (31.7%) cases of PML-RARalpha-positive M3 AML (P<0.01). Thus, the distinct gene expression profile of p73 further supports the notion that acute promyelocytic leukemia is a biologically different subset of AML. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
5. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200?mg/m2).
- Author
-
Palumbo, A., Bringhen, S., Bertola, A., Cavallo, F., Falco, P., Massaia, M., Bruno, B., Rus, C., Barbui, A., Caravita, T., Musto, P., Pescota, N., Rossini, F., Vignetti, M., and Boccadoro, M.
- Subjects
MULTIPLE myeloma ,CLINICAL trials ,DOSE-response relationship in biochemistry ,MEDICAL experimentation on humans ,HEALTH outcome assessment ,B cell lymphoma - Abstract
Several trials have shown the superior impact of high-dose melphalan (usually 200?mg/m
2 , MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100?mg/m2 , MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum ß2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P<0.0001). Complete remission was 35% after MEL100 and 48% after MEL200 (P=0.08). Median event-free survival (EFS) was 32 months in the MEL100 group and 42 months in the MEL200 group (P<0.005), but overall survival (OS) was not different. Transplant-related mortality was not significantly different. Haematological and extra-haematological toxicity was significantly reduced after MEL100. Despite the significant age difference, tandem MEL100 was less toxic than tandem MEL200, and MEL100 was inferior to MEL200 in terms of EFS but not in terms of OS. The intensified nonmyeloablative MEL100 regimen is an effective first-line treatment.Leukemia (2004) 18, 133-138. doi:10.1038/sj.leu.2403196 Published online 30 October 2003 [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
6. Treatment of elderly patients (=60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
- Author
-
Mandelli, F, Latagliata, R, Avvisati, G, Fazi, P, Rodeghiero, F, Leoni, F, Gobbi, M, Nobile, F, Gallo, E, Fanin, R, Amadori, S, Vignetti, M, Fioritoni, G, Ferrara, F, Peta, A, Giustolisi, R, Broccia, G, Petti, M C, and Lo-Coco, F
- Subjects
LEUKEMIA ,OLDER people - Abstract
In all, 134 elderly patients (median age 66 years, range 60-75 years) with newly diagnosed acute promyelocytic leukemia (APL) were enrolled in two successive protocols of the Italian multicenter group GIMEMA. All patients received an identical induction with all-trans retinoic acid and idarubicin; 116 (86%) entered complete remission (CR), two (2%) were resistant and 16 (12%) died during induction. After CR, 106 patients received further therapy whereas 10 did not, because of refusal (n = 5) or toxicity (n = 5). Consolidation consisted of three chemotherapy courses in the AIDA protocol (AIDA, 67 patients) or, since 1997, of an amended protocol including only the first cycle (amended AIDA, aAIDA, 39 patients). In the AIDA group, 43 patients (64%) completed consolidation, while seven (11%) and 17 (25%) patients were withdrawn after first and second courses, respectively; nine patients (13%) died in CR and 12 (18%) relapsed. In the aAIDA group, all patients received the assigned treatment; two patients (5%) died in CR and six (15%) relapsed. In the AIDA and aAIDA series, the 3-year overall and discase-free survival rates were 81 and 83% (P = NS), 73 and 72% (P = NS), respectively. We highlight here the frequency and severity of complications linked to intensive chemotherapy in this clinical setting and suggest that, in APL of the elderly, less intensive postremission therapy allows significant reduction of severe treatment-related toxicity and may be equally effective. [ABSTRACT FROM AUTHOR]
- Published
- 2003
7. Acute megakaryoblastic leukemia: experience of GIMEMA trials.
- Author
-
Pagano, L., Pulsoni, A., Vignetti, M., Mele, L., Fianchi, L., Petti, M.C., Mirto, S., Falcucci, P., Fazi, P., Broccia, G., Specchia, G., Di Raimondo, F., Pacilli, L., Leoni, P., Ladogana, S., Gallo, E., Venditti, A., Avanzi, G., and Camera, A.
- Subjects
ACUTE myeloid leukemia treatment ,CLINICAL trials - Abstract
The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them, 24 were AMeL. The incidence of AMeL among AML patients enrolled in GIMEMA trials was 0.6% (24/3603). Diagnosis was based on morphological criteria. Out of 11 cytogenetic studies performed two presented chromosome 3 abnormalities. Twelve patients (50%) reached a CR, five (21%) died in induction and seven (27%) were unresponsive. The median duration of CR was 35 weeks (range 10-441). Seven patients underwent transplantation procedures (1 BMT, 4 aBMT, 2 aPBSCT). Four patients died in CR due to chemotherapy-related complications. Comparing the CR rate between AMeL and the other cases of AML enrolled in GIMEMA trials, no differences were observed. These results were mirrored for different age groups. The median survival was 40 weeks. At present, after a followup of a minimum of 2 years, only two patients are alive in CR, all the others having died. A 5-year Kaplan-Meier curve shows a disease-free survival of 17% and an actuarial overall survival of 10%. AMeL is a rare form of AML. The CR duration and the overall survival in this group of patients are very poor, even if similar to those observed in other AML. Furthermore, a high number of deaths in CR were observed. On the basis of these data, a specific therapeutic approach, possibly with innovative treatments, should be evaluated. [ABSTRACT FROM AUTHOR]
- Published
- 2002
8. Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials.
- Author
-
Pagano, L., Pulsoni, A., Tosti, M. E., Caramatti, C., Cerri, R., Falcucci, P., Fazi, P., Fianchi, L., Martino, B., Mattei, D., Offidani, M., Pacilli, L., Pogliani, E. M., Rotoli, B., Specchia, G., Visani, G., Vignetti, M., Voso, M. T., Leone, G., and Mandelli, F.
- Subjects
LETTERS to the editor ,ACUTE myeloid leukemia ,CANCER - Abstract
Presents a letter to the editor commenting on an article about second malignancy after treatment of adult acute myeloid leukemia.
- Published
- 2004
- Full Text
- View/download PDF
9. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200?mg/m2).
- Author
-
Palumbo, A., Bringhen, S., Bertola, A., Cavallo, F., Falco, P., Massaia, M., Bruno, B., Rus, C., Barbui, A., Caravita, T., Musto, P., Pescota, N., Rossini, F., Vignetti, M., and Boccadoro, M.
- Subjects
- *
MULTIPLE myeloma , *CLINICAL trials , *DOSE-response relationship in biochemistry , *MEDICAL experimentation on humans , *HEALTH outcome assessment , *B cell lymphoma - Abstract
Several trials have shown the superior impact of high-dose melphalan (usually 200?mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100?mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum ß2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P<0.0001). Complete remission was 35% after MEL100 and 48% after MEL200 (P=0.08). Median event-free survival (EFS) was 32 months in the MEL100 group and 42 months in the MEL200 group (P<0.005), but overall survival (OS) was not different. Transplant-related mortality was not significantly different. Haematological and extra-haematological toxicity was significantly reduced after MEL100. Despite the significant age difference, tandem MEL100 was less toxic than tandem MEL200, and MEL100 was inferior to MEL200 in terms of EFS but not in terms of OS. The intensified nonmyeloablative MEL100 regimen is an effective first-line treatment.Leukemia (2004) 18, 133-138. doi:10.1038/sj.leu.2403196 Published online 30 October 2003 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.